KR102632796B1 - Ilt7 결합 분자 및 이의 사용 방법 - Google Patents

Ilt7 결합 분자 및 이의 사용 방법 Download PDF

Info

Publication number
KR102632796B1
KR102632796B1 KR1020237034385A KR20237034385A KR102632796B1 KR 102632796 B1 KR102632796 B1 KR 102632796B1 KR 1020237034385 A KR1020237034385 A KR 1020237034385A KR 20237034385 A KR20237034385 A KR 20237034385A KR 102632796 B1 KR102632796 B1 KR 102632796B1
Authority
KR
South Korea
Prior art keywords
ilt7
antibody
binding
seq
delete delete
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020237034385A
Other languages
English (en)
Korean (ko)
Other versions
KR20230148266A (ko
Inventor
캐서린 앤 부스던
줄리 앤 다우스웨이트
멜리사 마리 담슈로더
미구엘 엔젤 산주안
Original Assignee
비엘라 바이오, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 비엘라 바이오, 인크. filed Critical 비엘라 바이오, 인크.
Priority to KR1020247003436A priority Critical patent/KR102802736B1/ko
Publication of KR20230148266A publication Critical patent/KR20230148266A/ko
Application granted granted Critical
Publication of KR102632796B1 publication Critical patent/KR102632796B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Rehabilitation Therapy (AREA)
  • Transplantation (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
KR1020237034385A 2016-03-10 2017-03-09 Ilt7 결합 분자 및 이의 사용 방법 Active KR102632796B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020247003436A KR102802736B1 (ko) 2016-03-10 2017-03-09 Ilt7 결합 분자 및 이의 사용 방법

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662306125P 2016-03-10 2016-03-10
US62/306,125 2016-03-10
KR1020227029604A KR102603010B1 (ko) 2016-03-10 2017-03-09 Ilt7 결합 분자 및 이의 사용 방법
PCT/US2017/021616 WO2017156298A1 (en) 2016-03-10 2017-03-09 Ilt7 binding molecules and methods of using the same

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020227029604A Division KR102603010B1 (ko) 2016-03-10 2017-03-09 Ilt7 결합 분자 및 이의 사용 방법

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020247003436A Division KR102802736B1 (ko) 2016-03-10 2017-03-09 Ilt7 결합 분자 및 이의 사용 방법

Publications (2)

Publication Number Publication Date
KR20230148266A KR20230148266A (ko) 2023-10-24
KR102632796B1 true KR102632796B1 (ko) 2024-02-02

Family

ID=59790876

Family Applications (5)

Application Number Title Priority Date Filing Date
KR1020237034385A Active KR102632796B1 (ko) 2016-03-10 2017-03-09 Ilt7 결합 분자 및 이의 사용 방법
KR1020227029604A Active KR102603010B1 (ko) 2016-03-10 2017-03-09 Ilt7 결합 분자 및 이의 사용 방법
KR1020247003436A Active KR102802736B1 (ko) 2016-03-10 2017-03-09 Ilt7 결합 분자 및 이의 사용 방법
KR1020187028675A Active KR102439395B1 (ko) 2016-03-10 2017-03-09 Ilt7 결합 분자 및 이의 사용 방법
KR1020257011739A Pending KR20250051802A (ko) 2016-03-10 2017-03-09 Ilt7 결합 분자 및 이의 사용 방법

Family Applications After (4)

Application Number Title Priority Date Filing Date
KR1020227029604A Active KR102603010B1 (ko) 2016-03-10 2017-03-09 Ilt7 결합 분자 및 이의 사용 방법
KR1020247003436A Active KR102802736B1 (ko) 2016-03-10 2017-03-09 Ilt7 결합 분자 및 이의 사용 방법
KR1020187028675A Active KR102439395B1 (ko) 2016-03-10 2017-03-09 Ilt7 결합 분자 및 이의 사용 방법
KR1020257011739A Pending KR20250051802A (ko) 2016-03-10 2017-03-09 Ilt7 결합 분자 및 이의 사용 방법

Country Status (18)

Country Link
US (3) US11072652B2 (enExample)
EP (1) EP3426298A4 (enExample)
JP (4) JP6979976B2 (enExample)
KR (5) KR102632796B1 (enExample)
CN (2) CN114874322A (enExample)
AR (2) AR109450A1 (enExample)
AU (2) AU2017231833B2 (enExample)
BR (1) BR112018067951A2 (enExample)
CA (1) CA3017197A1 (enExample)
IL (2) IL321334A (enExample)
MX (2) MX2018010771A (enExample)
NZ (2) NZ746609A (enExample)
RU (1) RU2756109C2 (enExample)
SG (2) SG10202008769SA (enExample)
TW (1) TWI755380B (enExample)
UA (1) UA127731C2 (enExample)
WO (1) WO2017156298A1 (enExample)
ZA (1) ZA201806597B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2018010771A (es) 2016-03-10 2019-05-15 Viela Bio Inc Moleculas de union al transcrito 7 similar a inmunoglobulina (ilt7) y metodos de uso de las mismas.
WO2018119425A2 (en) * 2016-12-22 2018-06-28 Icahn School Of Medicine At Mount Sinai Anti-lilrb3 antibodies and methods of use thereof
US11732041B2 (en) * 2019-04-19 2023-08-22 Allogene Therapeutics, Inc. Antibodies against 4G7-derived chimeric antigen receptors
CA3159511A1 (en) * 2019-12-06 2021-06-10 William Rees Methods of treatment using ilt7 binding proteins
US20230055143A1 (en) * 2019-12-20 2023-02-23 Medimmune, Llc Compositions and Methods of Treating Cancer with Chimeric Antigen Receptors Targeting Glypican 3
WO2021203013A2 (en) * 2020-04-03 2021-10-07 Viela Bio, Inc. Methods of treating immune mediated pulmonary injury
EP4333877A1 (en) 2021-05-04 2024-03-13 Viela Bio, Inc. Methods of treatment of autoimmune disorders using ilt7 binding proteins
CN119630703A (zh) 2022-07-27 2025-03-14 维埃拉生物股份有限公司 包含免疫球蛋白样转录物7（ilt7）结合蛋白的配制剂
EP4634225A1 (en) 2022-12-12 2025-10-22 Viela Bio, Inc. Anti-ilt7 binding agents for the treatment and prevention of myositis
WO2024188356A1 (en) * 2023-03-16 2024-09-19 Inmagene Biopharmaceuticals (Hangzhou) Co., Ltd. Ilt7-targeting antibodies and uses thereof

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2096948A (en) 1935-12-20 1937-10-26 Anchor Steel & Conveyor Co Conveyer system
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4873192A (en) 1987-02-17 1989-10-10 The United States Of America As Represented By The Department Of Health And Human Services Process for site specific mutagenesis without phenotypic selection
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
DE768377T1 (de) 1988-09-02 1998-01-02 Dyax Corp Herstellung und Auswahl von Rekombinantproteinen mit verschiedenen Bindestellen
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
ZA902949B (en) 1989-05-05 1992-02-26 Res Dev Foundation A novel antibody delivery system for biological response modifiers
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
WO1991010737A1 (en) 1990-01-11 1991-07-25 Molecular Affinities Corporation Production of antibodies using gene libraries
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
ATE139258T1 (de) 1990-01-12 1996-06-15 Cell Genesys Inc Erzeugung xenogener antikörper
US5314995A (en) 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
CA2095633C (en) 1990-12-03 2003-02-04 Lisa J. Garrard Enrichment method for variant proteins with altered binding properties
WO1992018619A1 (en) 1991-04-10 1992-10-29 The Scripps Research Institute Heterodimeric receptor libraries using phagemids
ES2341666T3 (es) 1991-12-02 2010-06-24 Medimmune Limited Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos.
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
EP0733070A1 (en) 1993-12-08 1996-09-25 Genzyme Corporation Process for generating specific antibodies
EP1231268B1 (en) 1994-01-31 2005-07-27 Trustees Of Boston University Polyclonal antibody libraries
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
DE4440354A1 (de) 1994-11-11 1996-05-15 Hoechst Schering Agrevo Gmbh Kombinationen aus Phenylsulfonylharnstoff-Herbiziden und Safenern
US6706484B1 (en) 1995-08-18 2004-03-16 Morphosys Ag Protein/(poly)peptide libraries
ES2176484T3 (es) 1995-08-18 2002-12-01 Morphosys Ag Bancos de proteinas/(poli)peptidos.
JP2978435B2 (ja) 1996-01-24 1999-11-15 チッソ株式会社 アクリロキシプロピルシランの製造方法
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
ES2353268T3 (es) 1999-07-02 2011-02-28 Morphosys Ag Generacion de elementos de union especifica que se unen a (poli)peptidos codificados por fragmentos de adn genomico o est.
US6849425B1 (en) 1999-10-14 2005-02-01 Ixsys, Inc. Methods of optimizing antibody variable region binding affinity
JP2004500086A (ja) 2000-02-10 2004-01-08 アボット・ラボラトリーズ ヒトインターロイキン１８に結合する抗体とその調整方法および使用方法
US6897067B2 (en) 2000-11-03 2005-05-24 Regents Of The University Of Michigan Surface transfection and expression procedure
ATE352040T1 (de) 2000-11-17 2007-02-15 Univ Rochester In-vitro verfahren zur herstellung und identifizierung von immunglobulin moleküle in eukaryotischen zellen
US20030148316A1 (en) 2001-08-01 2003-08-07 Lipford Grayson B. Methods and compositions relating to plasmacytoid dendritic cells
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US7653594B2 (en) 2002-03-20 2010-01-26 Catalina Marketing Corporation Targeted incentives based upon predicted behavior
NZ571508A (en) 2002-05-24 2010-05-28 Schering Corp Neutralizing human anti-IGFR antibody
WO2004023973A2 (en) 2002-09-12 2004-03-25 Incyte Corporation Molecules for diagnostics and therapeutics
EP1647596A4 (en) 2003-07-18 2008-02-13 Mochida Pharm Co Ltd MONOCLONAL ANTIBODY AGAINST GLYCOPROTEIN VI THE BLOOD PLATE MEMBRANE
US9208495B2 (en) 2003-10-06 2015-12-08 Yellowpages.Com Llc Methods and apparatuses for advertisement presentation
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
KR101363120B1 (ko) * 2005-02-10 2014-02-13 베일러 리서치 인스티튜트 항-인터페론 알파 모노클로날 항체 및 사용 방법
WO2006124269A2 (en) * 2005-05-16 2006-11-23 Amgen Fremont Inc. Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders
PT2532681E (pt) 2005-12-20 2014-12-23 Sbi Biotech Co Ltd Anticorpos anti-ilt7
AU2012244391B2 (en) * 2005-12-20 2014-09-11 Sbi Biotech Co., Ltd. Anti-ILT7 antibody
KR20090029184A (ko) * 2006-04-07 2009-03-20 더 가브먼트 오브 더 유나이티드 스테이츠 오브 아메리카, 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 항체 조성물 및 신생물성 질병의 치료 방법
US7993648B2 (en) 2006-05-03 2011-08-09 The Regents of the Universitry of Colorado Immunostimulatory regimen comprising administering type 1 interferon and agonistic anti-CD40 antibody
US7781306B2 (en) 2007-06-20 2010-08-24 Semiconductor Energy Laboratory Co., Ltd. Semiconductor substrate and method for manufacturing the same
WO2010065536A2 (en) 2008-12-01 2010-06-10 The Board Of Regents Of The University Of Texas System Recombinant bone marrow stromal antigen-2 in the treatment of autoimmune diseases
HUE032917T2 (hu) 2009-09-03 2017-11-28 Medimmune Llc 1-es típusú interferon diagnosztikum
CA2780221A1 (en) 2009-11-04 2011-05-12 Fabrus Llc Methods for affinity maturation-based antibody optimization
EP2701742A4 (en) 2011-04-26 2015-03-18 Genentech Inc COMPOSITIONS AND METHOD FOR TREATING AUTOIMMUNE DISEASES
SG194233A1 (en) 2011-04-28 2013-12-30 Univ Leland Stanford Junior Identification of polynucleotides associated with a sample
US9427464B2 (en) 2011-11-22 2016-08-30 Chiome Bioscience Inc. Anti-human TROP-2 antibody having an antitumor activity in vivo
PL3431504T3 (pl) * 2012-01-31 2021-10-18 Sbi Biotech Co., Ltd. Przeciwciało przeciwko fosfolipazie D4
US8605807B1 (en) 2012-05-22 2013-12-10 Nigel Iain Stuart Macrae Communicating distinct data over a single frequency using multiple linear polarized signals
ES3023054T3 (en) * 2012-11-08 2025-05-29 Clearside Biomedical Inc Methods for the treatment of ocular disease in human subjects
US9114438B2 (en) 2013-05-21 2015-08-25 Applied Materials, Inc. Copper residue chamber clean
AU2015308625A1 (en) * 2014-08-29 2017-04-20 Sorrento Therapeutics, Inc. Antibody therapeutics that bind OprF and Oprl
MX2018010771A (es) 2016-03-10 2019-05-15 Viela Bio Inc Moleculas de union al transcrito 7 similar a inmunoglobulina (ilt7) y metodos de uso de las mismas.
CA3159511A1 (en) 2019-12-06 2021-06-10 William Rees Methods of treatment using ilt7 binding proteins
EP4333877A1 (en) 2021-05-04 2024-03-13 Viela Bio, Inc. Methods of treatment of autoimmune disorders using ilt7 binding proteins

Also Published As

Publication number Publication date
RU2018135550A (ru) 2020-04-10
CN114874322A (zh) 2022-08-09
AU2017231833A1 (en) 2018-10-11
JP2025134836A (ja) 2025-09-17
KR102439395B1 (ko) 2022-09-05
TWI755380B (zh) 2022-02-21
US20230250167A1 (en) 2023-08-10
TW201742874A (zh) 2017-12-16
US20220144940A1 (en) 2022-05-12
IL321334A (en) 2025-08-01
CN109414499A (zh) 2019-03-01
KR20220123344A (ko) 2022-09-06
US20200339673A1 (en) 2020-10-29
WO2017156298A1 (en) 2017-09-14
SG10202008769SA (en) 2020-10-29
SG11201807523PA (en) 2018-09-27
UA127731C2 (uk) 2023-12-20
AR122196A2 (es) 2022-08-24
JP6979976B2 (ja) 2021-12-15
ZA201806597B (en) 2023-04-26
MX2018010771A (es) 2019-05-15
NZ785821A (en) 2025-09-26
CN109414499B (zh) 2022-05-17
IL261653B2 (en) 2025-12-01
JP2019516392A (ja) 2019-06-20
CA3017197A1 (en) 2017-09-14
US11673950B2 (en) 2023-06-13
AR109450A1 (es) 2018-12-12
EP3426298A4 (en) 2019-11-27
JP7354212B2 (ja) 2023-10-02
JP7700190B2 (ja) 2025-06-30
AU2024203701A1 (en) 2024-06-27
NZ746609A (en) 2025-09-26
JP2024009808A (ja) 2024-01-23
JP2022043038A (ja) 2022-03-15
KR102802736B1 (ko) 2025-05-02
US11072652B2 (en) 2021-07-27
KR20230148266A (ko) 2023-10-24
MX2023010076A (es) 2023-09-06
KR102603010B1 (ko) 2023-11-16
RU2018135550A3 (enExample) 2020-07-23
BR112018067951A2 (pt) 2019-02-05
AU2017231833B2 (en) 2024-03-14
KR20240017421A (ko) 2024-02-07
EP3426298A1 (en) 2019-01-16
IL261653B1 (en) 2025-08-01
RU2756109C2 (ru) 2021-09-28
KR20180138201A (ko) 2018-12-28
IL261653A (en) 2018-10-31
KR20250051802A (ko) 2025-04-17

Similar Documents

Publication Publication Date Title
JP7700190B2 (ja) Ｉｌｔ７結合分子及びその使用方法
KR102261618B1 (ko) 신규한 il33 형태, il33의 돌연변이된 형태, 항체, 검정 및 이의 이용 방법
JP2023182705A (ja) 細胞傷害性ｔリンパ球関連タンパク質４（ｃｔｌａ－４）に対する新規モノクローナル抗体
CN108883173A (zh) 抗体和其使用方法
KR20220160584A (ko) 다중-특이적 항체를 통한 형질전환 성장 인자 베타 슈퍼패밀리 신호전달의 선택적 조정
KR20180028519A (ko) 항-TfR 항체 및 증식성 및 염증성 장애의 치료에서의 그의 용도
JP2017532290A (ja) Ｃｄ３イプシロンおよびｂｃｍａに対する二特異性抗体
KR20180132977A (ko) Tdp-43 특이적 결합 분자
WO2019184935A1 (zh) 抗cd27抗体、其抗原结合片段及其医药用途
KR20220145894A (ko) 신규 항체
CN108473586B (zh) 抗cd27抗体、其抗原结合片段及其医药用途
CN114075283A (zh) 结合人cd38的抗体、其制备方法和用途
RU2779128C2 (ru) Антитело к cd40, его антигенсвязывающий фрагмент и его медицинское применение
BR122024004758A2 (pt) Método de produção de um anticorpo anti-ilt7 e anticorpo produzido pelo método, e uso do mesmo
CN118804926A (zh) 用于治疗感染性病症的方法中的嗜乳脂蛋白（btn）3a活化抗体

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20231006

Application number text: 1020227029604

Filing date: 20220826

A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20231019

Comment text: Request for Examination of Application

PG1501 Laying open of application
E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20231110

A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20240129

Application number text: 1020227029604

Filing date: 20220826

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20240130

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20240130

End annual number: 3

Start annual number: 1

PG1601 Publication of registration